West Pharma (WST) Misses Q3 EPS by 10c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $2.03, $0.10 worse than the analyst estimate of $2.13. Revenue for the quarter came in at $686.9 million versus the consensus estimate of $728.11 million.
GUIDANCE:
West Pharma sees FY2022 revenue of $2.83-2.84 billion, versus the consensus of $2.98 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- DigitalOcean (DOCN) Tops Q3 EPS by 13c ; Offers Guidance
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
